CoChat
Sign Up
Cited by 2HIV/AIDS drug development and treatmentHIV Research and TreatmentDrug Transport and Resistance Mechanisms

Dicaffeoyltartaric Acid and Dicaffeoylquinic Acid HIV Integrase Inhibitors

Crosby, David C., Robinson, W. Edward·2011·HIV‐1 Integrase
DOI 10.1002/9781118015377.ch23
Open this paper in CoChat — free account

Abstract

This chapter contains sections titled: Introduction Discovery Characterization of L-CA as a Selective IN Inhibitor Controversy Surrounding In Vivo Site of Action For L-CA Mechanisms of Viral Resistance Stucture-Activity Relationship Studies L-CA in Combination with Reverse Transcriptase and Protease Inhibitors Summary Acknowledgments References

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/9781118015377.ch23

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. 10.1073/pnas.93.13.6326 · DOI
  2. 10.1016/S0042-6822(02)00042-9 · DOI
  3. King P., 1998, Resistance to the anti‐human immunodeficiency virus type 1 compound L‐chicoric acid results from a single mutation at amino acid 140 of integrase, J. Virol., 72, 8420, 10.1128/JVI.72.10.8420-8424.1998 · DOI
  4. 10.1016/0378-8741(96)01380-3 · DOI
  5. 10.1002/mnfr.200500216 · DOI
  6. 10.1021/np050447r · DOI
  7. Robinson W. E., 1996, Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: Inhibition of the core catalytic domain of human immunodeficiency virus integrase, Mol. Pharmacol., 50, 846, 10.1016/S0026-895X(25)09385-X · DOI
  8. 10.1021/jm010359d · DOI
  9. 10.1016/S0969-2126(01)00142-3 · DOI · Paper page
  10. Zhu K., 1999, Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids, J. Virol., 73, 3309, 10.1128/JVI.73.4.3309-3316.1999 · DOI
  11. 10.1016/j.virol.2004.06.005 · DOI
  12. 10.1124/mol.58.3.641 · DOI · Paper page
  13. 10.1128/AAC.46.10.3301-3303.2002 · DOI
  14. 10.1021/bi9907173 · DOI
  15. 10.1128/JVI.78.11.5835-5847.2004 · DOI
  16. 10.1126/science.287.5453.646 · DOI · Paper page
  17. 10.1529/biophysj.104.050286 · DOI
  18. 10.1016/S0006-3495(99)77453-9 · DOI
  19. 10.1021/jm000194t · DOI
  20. 10.1128/AAC.50.1.134-142.2006 · DOI
  21. 10.1073/pnas.96.23.13040 · DOI
  22. 10.1016/S0968-0896(01)00013-X · DOI
  23. 10.1021/jm9804735 · DOI
  24. 10.1016/j.bmc.2006.02.030 · DOI
  25. 10.1016/S0960-894X(00)00355-3 · DOI
  26. 10.1021/jm980531m · DOI
  27. 10.1016/S0968-0896(03)00372-9 · DOI
  28. 10.1021/jm049171v · DOI
  29. 10.1128/JVI.67.3.1169-1174.1993 · DOI
  30. 10.1016/S0166-3542(98)00037-0 · DOI
  31. 10.1016/S0166-3542(00)00083-8 · DOI
  32. Chou J., 1985, A Computer Software for Apple II Series or IBM PC and Manual
  33. Chou T. C., 1974, Relationships between inhibition constants and fractional inhibitions in enzyme‐catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types of mechanisms of inhibition, Pharmacology., 10, 235
  34. Chou T. C., 1991, Synergism and Antagonism in Chemotherapy, 61
  35. 10.1016/0065-2571(84)90007-4 · DOI · Paper page
  36. 10.1111/j.1432-1033.1981.tb06218.x · DOI
  37. 10.1097/00002030-200105040-00002 · DOI

Authors
Crosby, D. C., & Robinson, W. E.
Affiliations
University of California, Irvine (US)
ORCID
Venue
HIV‐1 Integrase
Publisher
Wiley
Published
2011-09-09
Pages
341-362
DOI
10.1002/9781118015377.ch23
OpenAlex
W1569339539
Cited by
2
References
2
Citations by year
2015: 1 · 2012: 1
Type
other
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
dicaffeoylquinic acids, HIV integrase inhibitors, integrase inhibitors, virus resistance, structure-activity relationship, reverse transcriptase inhibitors, protease inhibitors, highly active antiretroviral therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review